4'-Hydroxywogonin (8-Methoxyapigenin), a natural flavonoid with anti-inflammatory properties, reduced the production of pro-inflammatory cytokines (e.g., TNF-α, IL-6, and IL-1β), inhibited the TAK1/IKK/NF-κB signaling pathway, and reduced the phosphorylation of MAPKs and the PI3/Akt signaling pathway.

4'-Hydroxywogonin suppressed the expression of COX-2 and iNOS in LPS-stimulated RAW 264.7 macrophages after 24-hour incubation with 0.5–15 μM concentrations, as demonstrated by Western blot analysis. [1]
Treatment with 0.5–15 μM 4'-Hydroxywogonin for 24 hours reduced the production of nitric oxide (NO) and prostaglandin E2 (PGE2) in RAW 264.7 cells, as measured by Griess assay and ELISA, respectively. [1]
4'-Hydroxywogonin downregulated the expression of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) at the mRNA level after 4 hours (qRT-PCR) and at the protein level after 24 hours (Western blot) in RAW 264.7 macrophages. [1]
Pre-treatment with 0.5–15 μM 4'-Hydroxywogonin for 1 hour inhibited the LPS-induced interaction between TAK1 and TAB1 and suppressed downstream activation of the TAK1/IKK/NF-κB pathway, as shown by co-immunoprecipitation and Western blot performed 30–60 minutes post-stimulation. [1]
4'-Hydroxywogonin reduced phosphorylation of ERK, JNK, p38 MAPKs, and Akt in RAW 264.7 cells after 30 minutes of LPS stimulation, confirmed by Western blot following pre-treatment with 0.5–15 μM. [1]
4'-Hydroxywogonin significantly decreased intracellular reactive oxygen species (ROS) levels in LPS-stimulated RAW 264.7 cells, as detected by DCFH-DA fluorescence staining after 30–60 minutes of incubation. [1]

In an LPS-induced acute lung injury (ALI) mouse model, intraperitoneal injection of 4'-Hydroxywogonin at doses of 2.5, 5, or 10 mg/kg significantly suppressed the expression of COX-2 and iNOS in lung tissues, as shown by Western blot and immunohistochemistry. [1]
Treatment with 4'-Hydroxywogonin markedly reduced nitric oxide (NO) and prostaglandin E2 (PGE2) levels in bronchoalveolar lavage fluid (BALF), measured by Griess assay and ELISA. [1]
The levels of pro-inflammatory cytokines TNF-α and IL-6 in BALF decreased after 4'-Hydroxywogonin administration, indicating a systemic anti-inflammatory effect. [1]
4'-Hydroxywogonin alleviated lung tissue damage by reducing inflammatory cell infiltration and preserving alveolar structure. [1]
4'-Hydroxywogonin decreased the lung wet-to-dry weight ratio, suggesting a protective effect against LPS-induced pulmonary edema. [1]